Glofitamab monotherapy achieves durable responses in R/R DLBCL: three-year follow-up of NP30179

Download video

Glofitamab monotherapy achieves durable responses in R/R DLBCL: three-year follow-up of NP30179

105 views

VJHemOnc – Video Journal of Hematology & HemOnc

1 year ago

Glofitamab monotherapy achieves durable responses in R/R DLBCL: three-year follow-up of NP30179

16:37

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE

by SSBMT جمعية الخلايا الجذعية

$Phase II study of glofitamab in patients with R\/R LBCL$

2:40

Phase II study of glofitamab in patients with R\/R LBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

4:22

Treatment Options of B-Cell Lymphoma: Glofitamab vs. Epcoritamab - Blood Cancer Video Library 2023

by Global Resource for Advancing Cancer Education

6:47

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCL

by Blood Cancers Today

4:46

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

by ecancer

6:53

Glofitamab for Richter’s Transformation

by CLL Society

3:36

Michael Dickinson, MBBS, DMedSc, on Glofitamab Combination Trials Underway

by Blood Cancers Today

2:54

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Update on Phase I\/II study of glofitamab monotherapy in R\/R MCL$

2:18

Update on Phase I\/II study of glofitamab monotherapy in R\/R MCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Relapsed and Refractory Diffuse Large B-Cell Lymphoma$

46:48

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

by Lymphoma Research Foundation

$The Phase III STARGLO trial: Glofit-GemOx versus R-GemOx for R\/R DLBCL$

6:35

The Phase III STARGLO trial: Glofit-GemOx versus R-GemOx for R\/R DLBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Management of Relapsed and Refractory Large B Cell Lymphoma-Latest BSH UK Guidelines$

8:17

Management of Relapsed and Refractory Large B Cell Lymphoma-Latest BSH UK Guidelines

by Haematology, Morphology, FRCPath Exams

2:52

Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Glofitamab - Blood Cancers OncTalk 2023

by Global Resource for Advancing Cancer Education

2:57

A Phase II study of glofitamab plus Pola-R-CHP for patients with high-risk DLBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

3:02

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma

by Global Resource for Advancing Cancer Education

$Updates from the Phase II trials of glofitamab and epcoritamab for R\/R LBCL$

1:49

Updates from the Phase II trials of glofitamab and epcoritamab for R\/R LBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Advantages of bispecific antibodies for lymphoma: mosunetuzumab, epcoritamab \& glofitamab$

1:31

Advantages of bispecific antibodies for lymphoma: mosunetuzumab, epcoritamab \& glofitamab

by VJHemOnc – Video Journal of Hematology \& HemOnc

$A Phase I\/II trial of glofitamab monotherapy in R\/R MCL$

1:45

A Phase I\/II trial of glofitamab monotherapy in R\/R MCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Glofitamab for Relapsed\/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24$

3:26

Glofitamab for Relapsed\/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24

by HealthTree Foundation for Blood Cancers

$Glofitamab monotherapy achieves durable responses in R\/R DLBCL: three-year follow-up of NP30179$

5:59

Glofitamab monotherapy achieves durable responses in R\/R DLBCL: three-year follow-up of NP30179

by VJHemOnc – Video Journal of Hematology \& HemOnc

1:29

STARGLO 2-year follow-up: durability of responses in patients with DLBCL receiving Glofitamab-GemOx

by VJHemOnc – Video Journal of Hematology \& HemOnc

$The emerging potential of bispecific antibodies as monotherapy \& in combination for B-cell lymphoma$

5:12

The emerging potential of bispecific antibodies as monotherapy \& in combination for B-cell lymphoma

by VJHemOnc – Video Journal of Hematology \& HemOnc

$COLUMVI (glofitamab-gxbm)- relapsed or refractory diffuse large B-cell lymphoma$

1:57

COLUMVI (glofitamab-gxbm)- relapsed or refractory diffuse large B-cell lymphoma

by Pharmacy Talk USA

Best on Vidoe

Glofitamab monotherapy achieves durable responses in R/R DLBCL: three-year follow-up of NP30179